Syndax Pharmaceuticals, Inc. — Income Charts
30 years of history · ending 2025-12-31 · SEC EDGAR
Revenue↑+23.4% +$33M
$172M
R&D↑+193.2% +$171M
$259M
SG&A↑+611.9% +$154M
$180M
D&A↓-86.0% -$37M
$6M
Operating Income↓-1141.5% -$299M
$-273M
EBITDA↓-485.8% -$336M
$-267M
Interest Expense↓-99.7% -$2M
$6K
Tax Provision
$433K
Net Income↓-1245.1% -$310M
$-285M
Operating Margin↓-177.2pts
-158.4%
Net Margin↓-183.4pts
-165.6%